

## Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes reports the following transactions under ISIN DK0060336014, Novozymes B shares under the symbol NZYM B.

**February 2, 2024**

Company announcement No. 08

The Executive Leadership Team has on February 1<sup>st</sup>, 2024 from Novozymes A/S received the allocated shares from the incentive program for the period 2021-2023. An overview of the number and value of shares allotted is provided on the following pages.

### Contact information

---

#### Investor Relations

Tobias Bjorklund	+45 3077 8682	<a href="mailto:tobb@novonesis.com">tobb@novonesis.com</a>
Anders Enevoldsen	+45 5350 1453	<a href="mailto:adev@novonesis.com">adev@novonesis.com</a>

---

#### About Novonesis

Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.

**Novozymes A/S, part of  
Novonesis Group**  
Krogshøjvej 36  
2880 Bagsvaerd  
Denmark

**novonesis.com**

1.	<b>Details of the person discharging managerial responsibilities/person closely associated</b>					
a)	Name	Ester Baiget				
2.	<b>Reason for the notification</b>					
a)	Position/status	CEO and president				
b)	Initial notification/ Amendment	Initial notification				
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>					
a)	Name	Novozymes A/S				
b)	LEI	529900T6WZNXD2R3JW38				
4.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>					
a)	Description of the financial instrument, type of instrument  Identification code	B-Shares  DK0060336014				
b)	Nature of the transaction	Shares received as part of incentive program				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 371.6</td> <td>14,923 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 371.6	14,923 shares
Price(s)	Volume(s)					
DKK 371.6	14,923 shares					
d)	Aggregated information - Aggregated volume - Price	Number of shares: 14,923 Average price, DKK: 371.6 Transaction value, DKK: 5,545,386.80				
e)	Date of transaction	February 1, 2024				
f)	Place of the transaction	Outside a trading venue				

1.	<b>Details of the person discharging managerial responsibilities/person closely associated</b>		
a)	Name	Amy Louise Byrick	
2.	<b>Reason for the notification</b>		
a)	Position/status	Executive Vice President, Human Health Biosolutions	
b)	Initial notification/ Amendment	Initial notification	
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Novozymes A/S	
b)	LEI	529900T6WZNXD2R3JW38	
4.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	B-Shares	
	Identification code	DK0060336014	
b)	Nature of the transaction	Shares received as part of incentive program	
c)	Price(s) and volume(s)	<b>Price(s)</b>	<b>Volume(s)</b>
		DKK 371.6	3,959 shares
d)	Aggregated information	Number of shares: 3,959	
	- Aggregated volume	Average price, DKK: 371.6	
	- Price	Transaction value, DKK: 1,471,164.40	
e)	Date of transaction	February 1, 2024	
f)	Place of the transaction	Outside a trading venue	

1.	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name	Anders Lund
2.	<b>Reason for the notification</b>	
a)	Position/status	Executive Vice President, Chief Operating Officer
b)	Initial notification/ Amendment	Initial notification
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Novozymes A/S
b)	LEI	529900T6WZNZXD2R3JW38
4.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	B-Shares
	Identification code	DK0060336014
b)	Nature of the transaction	Shares received as part of incentive program
c)	Price(s) and volume(s)	<b>Price(s)</b>
		<b>Volume(s)</b>
		DKK 371.6
		10,815 shares
d)	Aggregated information	Number of shares: 10,815
	- Aggregated volume	Average price, DKK: 371.6
	- Price	Transaction value, DKK: 4,018,854.00
e)	Date of transaction	February 1, 2024
f)	Place of the transaction	Outside a trading venue

1.	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name	Claus Crone Fuglsang
2.	<b>Reason for the notification</b>	
a)	Position/status	Executive Vice President, Chief Scientific Officer
b)	Initial notification/ Amendment	Initial notification
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Novozymes A/S
b)	LEI	529900T6WZNXD2R3JW38
4.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	B-Shares
	Identification code	DK0060336014
b)	Nature of the transaction	Shares received as part of incentive program
c)	Price(s) and volume(s)	<b>Price(s)</b>
		<b>Volume(s)</b>
		DKK 371.6
		6,992 shares
d)	Aggregated information	Number of shares: 6,992
	- Aggregated volume	Average price, DKK: 371.6
	- Price	Transaction value, DKK: 2,598,227.20
e)	Date of transaction	February 1, 2024
f)	Place of the transaction	Outside a trading venue

1.	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name	Morten Enggaard Rasmussen
2.	<b>Reason for the notification</b>	
a)	Position/status	Executive Vice President, People & Stakeholder Relations
b)	Initial notification/ Amendment	Initial notification
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Novozymes A/S
b)	LEI	529900T6WZNXD2R3JW38
4.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument  Identification code	B-Shares  DK0060336014
b)	Nature of the transaction	Shares received as part of incentive program
c)	Price(s) and volume(s)	<b>Price(s)</b>
		<b>Volume(s)</b>
		DKK 371.6
		2,828 shares
d)	Aggregated information - Aggregated volume - Price	Number of shares: 2,828 Average price, DKK: 371.6 Transaction value, DKK: 1,050,884.80
e)	Date of transaction	February 1, 2024
f)	Place of the transaction	Outside a trading venue

1.	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name	Tina Sejersgård Fanø
2.	<b>Reason for the notification</b>	
a)	Position/status	Executive Vice President, Planetary Health Biosolutions
b)	Initial notification/ Amendment	Initial notification
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Novozymes A/S
b)	LEI	529900T6WNZXD2R3JW38
4.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument  Identification code	B-Shares  DK0060336014
b)	Nature of the transaction	Shares received as part of incentive program
c)	Price(s) and volume(s)	<b>Price(s)</b>
		<b>Volume(s)</b>
		DKK 371.6
		10,815 shares
d)	Aggregated information - Aggregated volume - Price	Number of shares: 10,815 Average price, DKK: 371.6 Transaction value, DKK: 4,018,854.00
e)	Date of transaction	February 1, 2024
f)	Place of the transaction	Outside a trading venue